TD-8954

DRUG2 trials

Sponsors

Theravance Biopharma, Takeda

Conditions

Enteral Feeding IntoleranceGastrointestinal Motility Disorder

Phase 1

A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects

TerminatedNCT01644240

Theravance BiopharmaGastrointestinal Motility Disorder

Start: 2012-09-30End: 2012-12-31Updated: 2017-08-02

A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance

CompletedNCT01953081

TakedaEnteral Feeding Intolerance

Start: 2014-01-31End: 2014-10-31Updated: 2020-02-18

Related Papers

Blinded, Double‐Dummy, Parallel‐Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5‐Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding Intolerance

Journal of Parenteral and Enteral Nutrition2020-01-2824 citations